Clinical Efficacy of Ustekinumab in Crohn's Disease

Who May Qualify: - Patients aged 18 years and older; - Patients who were first prescribed Ustekinumab between January 1 and December 31, 2024 - Patients who provided written willing to sign a consent form to participate in the study Who Should NOT Join This Trial: - Contraindications to the use of the drug Ustekinumab per the current instructions: - Clinically significant active infection (active tuberculosis, active viral hepatitis); - Pregnancy and lactation; - A history of clinically significant, in the opinion of the investigator, psychiatric disorders that may interfere with the study procedures and compliance with the drug regimen; - Ulcerative colitis; - Malignant gastrointestinal diseases in history or at the time of inclusion in the study; - Decompensated chronic diseases of the liver, kidneys, cardiovascular system, systemic vasculitis, diabetes mellitus; - Abuse of alcohol or psychoactive drugs within 1 year before the start of this study (as reported by the patient); - Participation in an interventional clinical trial. Always talk to your doctor about whether this trial is right for you.